TY - JOUR T1 - 哪些患者SaPHe结节病相关性肺动脉高压？JF - 欧洲呼吸杂志JO - EUR呼吸杂志DO - 10.1183 / 13993003.00700-2020 VL - 55 - 5 SP - 2000700 AU - 可见，丹尼尔AU - Boucly，AthénaïsAU - 亨伯特，马克AU - Weatherald，杰森Y1 - 2020 /05/01 UR - //www.qdcxjkg.com/content/55/5/2000700.abstract N2 - 肺动脉高压（PH）是结节病一个很好的描述和临床上重要的并发症。The epidemiology of sarcoidosis-associated pulmonary hypertension (SaPH) varies depending on the characteristics of the population analysed, but ranges from 3–75%, depending on method of diagnosis (i.e. echocardiography versus right heart catheterisation (RHC)) and severity of underlying sarcoidosis [1–4]. Elevation of pulmonary arterial pressure in sarcoidosis can occur via a number of mechanisms (figure 1) [5, 6] and, as such, SaPH has remained under group 5 (PH with unclear and/or multifactorial mechanisms) in the recent 6th World Symposium on Pulmonary Hypertension [7]. The breadth of pathophysiologic mechanisms that lead to PH is fairly unique to sarcoidosis, which makes SaPH an interesting but complicated entity.Pre-capillary pulmonary hypertension is a rare and heterogenous complication in sarcoidosis. 6-min walking distance is a robust and consistent prognostic factor, but the role of pulmonary arterial hypertension-targeted treatments remains controversial. http://bit.ly/2J27Yps ER -